Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAllison M. BockACAmrita ChauhanLFLorenzo Falchi

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows inferior progression free survival in trial ineligible patients with high-risk clinical characteristics.

Key Points

  • Overall response rate was 48.7% in patients treated with epcoritamab for R/R LBCL.
  • Cytokine release syndrome occurred in 33% of patients; immune effects affected 12% of patients.
  • This multicenter retrospective study assessed clinical characteristics of patients treated with epcoritamab.
  • Trial ineligible patients exhibited significantly inferior survival outcomes, suggesting real-world challenges.

Cite This Study

Bock et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deefhttps://doi.org/10.1182/blood-2025-3739
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study2025
  2. 2Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations2025
  3. 3Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress2025
  4. 4Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  5. 5Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025